NMR
Overvalued by 160.8% based on the discounted cash flow analysis.
Market cap | $18.24 Billion |
---|---|
Enterprise Value | $9.85 Trillion |
Dividend Yield | $0.39 (5.349419531072161%) |
Earnings per Share | $52.69 |
Beta | 0.57 |
Outstanding Shares | 2,955,740,093 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 7.62 |
---|---|
PEG | 7.57 |
Price to Sales | 0.01 |
Price to Book Ratio | 0.01 |
Enterprise Value to Revenue | 3 |
Enterprise Value to EBIT | 32.42 |
Enterprise Value to Net Income | 30 |
Total Debt to Enterprise | 1.56 |
Debt to Equity | 4.32 |
No data
No data